Vertebrate Antibodies Limited (VAL) is an emerging biotech company with a wealth of experience in the development of high performance antibodies to support the life science communities.

VAL was cofounded and is, presently led by research scientists: Ayham Alnabulsi, Beatriz Cash and Steve Bird. The combined expertise of the management team on hybridoma technology, bioinformatics and protein modelling formed the cornerstones of the business. Based on their wealth of experience, the team introduced fundamental technical modifications to the conventional methods, significantly increasing the efficiency and productivity of the technology as well as improving the specificity, reliability and quality of the antibodies produced. These improvements enabled VAL to expand their initial company plans from targeting human cancer markers to new territories such as the aquaculture industry.

VAL is a company formed by scientists to serve scientists. Their focus is to satisfy key research areas and cover a wide spectrum of veterinary species including lower vertebrates to allow scientists to undertake new research and help in the development of novel diagnostic and therapeutic strategies. With a strong team of staff, scientific advisors, a network of international collaborators and distributors, VAL can meet the needs of the customers and make provisions for the demands of specific emerging markets.

To continue to thrive as a business over the next ten years and beyond, VAL will continue developing high quality products for specific niche markets. Their vision is to become the leading company in all of life science research markets through offering new and lasting products and solutions that make a difference.